

# C O N T E N T S

---

<i>LIST OF ILLUSTRATIONS</i>	ix
<i>LIST OF TABLES</i>	xi
<i>ACKNOWLEDGMENTS</i>	xiii
<i>LIST OF ABBREVIATIONS AND ACRONYMS</i>	xvii
INTRODUCTION	
The Gatekeeper	1
CHAPTER ONE	
Reputation and Regulatory Power	33
<i>PART ONE: ORGANIZATIONAL EMPOWERMENT AND CHALLENGE</i>	
CHAPTER TWO	
Reputation and Gatekeeping Authority: The Federal Food, Drug and Cosmetic Act of 1938 and Its Aftermath	73
CHAPTER THREE	
The Ambiguous Emergence of American Pharmaceutical Regulation, 1944–1961	118
CHAPTER FOUR	
Reputation and Power Crystallized: Thalidomide, Frances Kelsey, and Phased Experiment, 1961–1966	228
CHAPTER FIVE	
Reputation and Power Institutionalized: Scientific Networks, Congressional Hearings, and Judicial Affirmation, 1963–1986	298
CHAPTER SIX	
Reputation and Power Contested: Emboldened Audiences in Cancer and AIDS, 1977–1992	393
<i>PART TWO: PHARMACEUTICAL REGULATION AND ITS AUDIENCES</i>	
CHAPTER SEVEN	
Reputation and the Organizational Politics of New Drug Review	465

CHAPTER EIGHT	
The Governance of Research and Development: Gatekeeping Power, Conceptual Guidance, and Regulation by Satellite	544
CHAPTER NINE	
The Other Side of the Gate: Reputation, Power, and Post-Market Regulation	585
CHAPTER TEN	
The Détente of Firm and Regulator	635
CHAPTER ELEVEN	
American Pharmaceutical Regulation in International Context: Audiences, Comparisons, and Dependencies	686
CHAPTER TWELVE	
Conclusion: A Reputation in Relief	727
<i>PRIMARY SOURCES AND ARCHIVAL COLLECTIONS</i>	753
<i>INDEX</i>	759